Daniel D. Karp

18.8k total citations · 4 hit papers
217 papers, 9.4k citations indexed

About

Daniel D. Karp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daniel D. Karp has authored 217 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 88 papers in Pulmonary and Respiratory Medicine and 70 papers in Molecular Biology. Recurrent topics in Daniel D. Karp's work include Lung Cancer Treatments and Mutations (49 papers), Cancer Genomics and Diagnostics (31 papers) and Colorectal Cancer Treatments and Studies (22 papers). Daniel D. Karp is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Cancer Genomics and Diagnostics (31 papers) and Colorectal Cancer Treatments and Studies (22 papers). Daniel D. Karp collaborates with scholars based in United States, China and Canada. Daniel D. Karp's co-authors include Philip Bonomi, Mark S. Huberman, R. Lotan, P. Santabárbara, Eric K. Rowinsky, Abraham Chachoua, Lisa A. Hammond, James R. Rigas, Román Pérez-Soler and Everett E. Vokes and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel D. Karp

210 papers receiving 9.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 1.1k citations Frank V. Fossella, Vincent A. Miller et al. Journal of Clinical Oncology profile →
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck

1990 1.1k citations Daniel D. Karp et al. profile →
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 893 citations Daniel D. Karp et al. Journal of Clinical Oncology profile →
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer

2003 862 citations Daniel D. Karp et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Daniel D. Karp	4.8k	3.8k	2.9k	1.6k	1.0k	217	9.4k
Dick J. Richel	4.5k 0.9×	1.7k 0.4×	3.5k 1.2×	2.2k 1.4×	1.6k 1.6×	107	9.6k
Alessandro Morabito	4.8k 1.0×	3.4k 0.9×	1.7k 0.6×	1.7k 1.1×	443 0.4×	217	7.2k
Sabino De Placido	7.8k 1.6×	4.5k 1.2×	4.4k 1.5×	3.7k 2.3×	1.2k 1.2×	381	14.0k
Federico Innocenti	4.9k 1.0×	1.5k 0.4×	3.3k 1.1×	1.2k 0.7×	655 0.6×	211	7.8k
Martin J. Edelman	4.6k 1.0×	4.3k 1.1×	2.0k 0.7×	946 0.6×	1.0k 1.0×	302	8.7k
David Khayat	5.3k 1.1×	2.6k 0.7×	2.4k 0.8×	1.4k 0.9×	1.1k 1.1×	108	8.4k
H. Cortés-Funes	6.4k 1.3×	2.6k 0.7×	1.8k 0.6×	1.3k 0.8×	2.1k 2.0×	192	9.6k
Chris Twelves	6.5k 1.4×	2.3k 0.6×	2.2k 0.7×	1.7k 1.1×	751 0.7×	183	9.7k
Wael Sakr	3.0k 0.6×	5.2k 1.4×	3.1k 1.1×	2.2k 1.4×	2.9k 2.8×	214	11.4k
Giampietro Gasparini	4.1k 0.9×	1.5k 0.4×	5.0k 1.7×	3.4k 2.2×	707 0.7×	170	9.8k

Countries citing papers authored by Daniel D. Karp

Since Specialization

Citations

This map shows the geographic impact of Daniel D. Karp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Karp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Karp more than expected).

Fields of papers citing papers by Daniel D. Karp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel D. Karp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Karp. The network helps show where Daniel D. Karp may publish in the future.

Co-authorship network of co-authors of Daniel D. Karp

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel D. Karp. A scholar is included among the top collaborators of Daniel D. Karp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel D. Karp. Daniel D. Karp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Piha‐Paul, Sarina A., Chieh Tseng, Cheuk Hong Leung, et al.. (2024). Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN loss. 1 indexed citations

Gouda, Mohamed A., Aung Naing, Ecaterina E. Dumbrava, et al.. (2024). A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3152–3152. 1 indexed citations

Piha‐Paul, Sarina A., Chieh Tseng, Cheuk Hong Leung, et al.. (2024). Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. npj Precision Oncology. 8(1). 166–166. 4 indexed citations

Son, Ji, Heather Lin, Siqing Fu, et al.. (2023). Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. SHILAP Revista de lepidopterología. 6(1). 10–18. 1 indexed citations

Nelson, Blessie Elizabeth, Apostolia M. Tsimberidou, Xueyao Fu, et al.. (2023). A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. The Oncologist. 28(12). 1100–e1292. 6 indexed citations

Altan, Mehmet, Denái R. Milton, Bülent Yılmaz, et al.. (2023). Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer. Cancer. 129(17). 2685–2693. 6 indexed citations

Ahmed, Jibran, Bettzy Stephen, Sarina A. Piha‐Paul, et al.. (2023). Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 130(3). 400–409. 11 indexed citations

Karp, Daniel D., D. Ross Camidge, J. Infante, et al.. (2022). Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 49. 101430–101430. 25 indexed citations

Fu, Siqing, Shuyang Yao, Yuan Yuan, et al.. (2022). Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology. 41(9). 1725–1734. 50 indexed citations

10.

Gouda, Mohamed A., Helen J. Huang, Sarina A. Piha‐Paul, et al.. (2022). Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision Oncology. 6(6). e2100512–e2100512. 28 indexed citations

11.

Hong, David S., Kathleen N. Moore, Johanna C. Bendell, et al.. (2021). Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical Cancer Research. 27(7). 1864–1874. 37 indexed citations

12.

Hahn, Andrew W., Jad Chahoud, Matthew T. Campbell, et al.. (2021). Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Investigational New Drugs. 39(5). 1405–1410. 37 indexed citations

13.

Hess, Kenneth R., Roman Groisberg, David S. Hong, et al.. (2018). Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 120. 137–141. 27 indexed citations

14.

Fountzilas, Elena, Filip Jankú, Siqing Fu, et al.. (2018). A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemotherapy and Pharmacology. 82(5). 877–885. 5 indexed citations

15.

George, Goldy C., Sarina A. Piha‐Paul, Vivek Subbiah, et al.. (2018). Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research. 21(3). e10348–e10348. 16 indexed citations

16.

Kehl, Kenneth L., Siqing Fu, Goldy C. George, et al.. (2017). Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research. 23(15). 4155–4162. 4 indexed citations

17.

Tang, Chad, James W. Welsh, Patricia M. de Groot, et al.. (2016). Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research. 23(6). 1388–1396. 251 indexed citations

18.

Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics. 15(10). 2475–2485. 73 indexed citations

19.

Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research. 76(13). 3690–3701. 149 indexed citations

20.

Maurer, L. Herbert, et al.. (1977). Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II).. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(3). 477–9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact